Invesaro

Stocks Health care ELUT

NASDAQ · Health care

Elutia Inc. (ELUT)

Elutia Inc. brought in $12.1M of revenue over the twelve months to June 30, 2026, up 69.0% from a year earlier. Net income was $51.8M, a net margin of 426.9%. In fiscal 2025 capital spending exceeded operating cash flow by $46.7M. At June 30, 2026 it held $19.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Revenue (last 12 months)
$12.1M
+69.0% year on year
Net margin
426.9%

What Elutia Inc. does

Elutia Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ELUT.

Revenue and profit by year

Revenue
FY20: $42.9M $42.9M FY20FY20: $42.7M $42.7M FY20FY21: $47.4M $47.4M FY21FY22: $23.8M $23.8M FY22FY23: $24.7M $24.7M FY23FY24: $14.5M $14.5M FY24FY25: $12.3M $12.3M FY25
Net income
FY20: -$11.9M -$11.9M FY20FY20: -$21.8M -$21.8M FY20FY21: -$24.8M -$24.8M FY21FY22: -$32.9M -$32.9M FY22FY23: -$37.7M -$37.7M FY23FY24: -$53.9M -$53.9M FY24FY25: $53.4M $53.4M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$12.3M-$26.9M$53.4M$0.87-$46.7M
2024$14.5M-$30.7M-$53.9M-$1.86-$23.3M
2023$24.7M-$30.5M-$37.7M-$2.07-$22.1M
2022$23.8M-$35.2M-$32.9M-$2.38-$22M
2021$47.4M-$23M-$24.8M-$2.38-$15.8M
2020$42.7M-$13.6M-$21.8M-$8.88-$14.3M

Latest SEC filings

What Elutia Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 21, 2026
    Acquisition or sale completed 8-K
  2. August 14, 2026
    Employee stock plan registration S-8
  3. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026
  4. August 14, 2026
    Passive stake changed SCHEDULE 13G/A
  5. August 13, 2026
    Quarterly results 8-K
  6. August 11, 2026
    Passive stake (5% or more) SCHEDULE 13G
  7. August 7, 2026
    Stock exchange listing notice 8-K
  8. July 20, 2026
    Material agreement 8-K
  9. June 16, 2026
    Executive or director change 8-K
  10. May 15, 2026
    Quarterly report 10-Q · period to March 31, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 14, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about ELUT

What does Elutia Inc. do?

Elutia Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ELUT.

Is Elutia Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $51.8M on revenue of $12.1M, a net margin of 426.9%.

How much revenue does Elutia Inc. make?

Over the twelve months to June 30, 2026 Elutia Inc. reported revenue of $12.1M. That is 69.0% more than a year earlier.

When did Elutia Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 14, 2026.

Similar companies

AMGN
Amgen Inc
GILD
Gilead Sciences, Inc.
BIIB
Biogen Inc.
BNTX
BioNTech SE
NBIX
Neurocrine Biosciences Inc
EXEL
Exelixis, Inc.

Follow ELUT

Get an email when Elutia Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ELUT: get an email when it files

Where the numbers come from

Financial figures are the values Elutia Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.